Neurophysiological correlates of memory change in children with fetal alcohol spectrum disorders treated with choline

Anita J Fuglestad1, Neely C Miller2, Birgit A Fink3

  • 1Department of Psychology, University of North Florida, Jacksonville, FL, United States.

Frontiers in Psychology
|October 13, 2022
PubMed

Insights

Choline supplementation in children with Fetal Alcohol Spectrum Disorder (FASD) showed a link between memory performance and brain activity. Further research is needed to confirm choline

Area of Science:

  • Neuroscience
  • Developmental Psychology
  • Pediatrics

Background:

  • Animal models suggest choline supplementation can mitigate Fetal Alcohol Spectrum Disorder (FASD) related deficits.
  • Previous research indicated postnatal choline improved recognition memory in children with FASD.
  • This study investigates the neurophysiological basis of that observed memory improvement.

Purpose of the Study:

  • To explore the neurophysiological correlates of improved recognition memory in children with FASD following choline supplementation.
  • To examine the relationship between event-related potentials (ERPs) and memory performance in children with FASD.

Main Methods:

  • Followed 24 children with FASD for 9 months in a choline supplementation trial.
  • Assessed recognition memory using delayed recall on a 9-step elicited imitation task.
  • Measured neurophysiological correlates of memory using event-related potentials (ERPs).

Main Results:

  • Delayed recall memory performance correlated significantly with specific ERP components (Nc amplitude and PSW area under the curve).
  • Observed correlations suggest a link between memory function and neurophysiological activity in children with FASD.
  • No significant differences in ERPs were found between choline and placebo groups post-trial.

Conclusions:

  • The findings suggest a relationship between memory performance and neurophysiological status in children with FASD.
  • The small sample size limits definitive conclusions regarding choline's treatment effect on ERPs.
  • Further investigation is warranted to understand choline's impact on FASD neurophysiology.
Abstract

Related Concept Videos

Role of Neurotransmitters in Memory01:23

Role of Neurotransmitters in Memory

Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
 Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
764
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
191
Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
160
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
247
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
628